Learn before you link.

MN Pharmaceuticals was established in 1923 and developed a healthcare and pharmaceutical heritage spanning more than a century. In 2012, Amgen acquired MN Pharmaceuticals in a publicly announced transaction. Amgen subsequently renamed the company Gensenta in 2020.

The name rights relating to MN Pharmaceuticals were later transferred to the current MN ownership structure, and MN Nutra represents the fourth-generation continuation of the healthcare heritage that began more than a century ago.

MN Nutra is the fourth-generation continuation of the MN Pharmaceuticals healthcare heritage, combining more than a century of formulation experience with independently developed Micro Matrix Technology and modern finished-product research.

Important: MN Nutra is not owned by, affiliated with, or endorsed by Amgen or Gensenta. The products, technology, and research are independently developed by the current MN ownership structure.

Mehmet Nevzat Pisak, President of MN Nutra, has spent more than 20 years working on pharmaceutical and nutritional formulations designed to improve delivery efficiency, enhance product performance and reduce formulation-related side effects. His publicly searchable patent portfolio includes multiple invention families covering pharmaceutical combinations, gastroprotective approaches, oral delivery systems, curcuminoid formulations and bioavailability-focused compositions.

Key takeaway for affiliates: When discussing heritage, always use the approved language. Say 'fourth-generation continuation of MN Pharmaceuticals healthcare heritage' — never claim affiliation with Amgen or Gensenta. The heritage is about formulation expertise and scientific tradition, not corporate ownership.

Micro Matrix Technology is MN Nutra's proprietary formulation platform. It was independently developed by the current MN ownership structure and is not derived from any Amgen or Gensenta technology.

The core challenge: Many beneficial compounds (curcumin, CBD from hemp, beta-glucan) have poor water solubility and low oral bioavailability. This means the body absorbs only a fraction of what you swallow. Micro Matrix Technology addresses this through a multi-stage micronization and matrix-embedding process.

How it works — the seven principles: (1) Particle size reduction to increase surface area. (2) Amorphous solid dispersion to improve dissolution rate. (3) Matrix embedding for stability and controlled release. (4) Surfactant integration for wetting and solubilisation. (5) Gastric protection where needed. (6) Coordinated multi-ingredient release profiles. (7) Manufacturing scalability using GRAS excipients only.

What Micro Matrix delivers: Higher peak plasma concentration (Cmax), greater total exposure (AUC), faster time to peak (Tmax), and lower variability between individuals. COMPLIANCE NOTE: describe this as better absorption. Never describe it as reaching a therapeutic level, and never present absorption as proof of a health outcome.

Evidence: The CBDNext Supra Capsule human pharmacokinetic study (Journal of Cannabis Research, 2025) showed a higher peak plasma level and greater total exposure than a standard CBD isolate from hemp capsule, in 9 healthy adults on a single 40 mg dose under fed conditions. NovoCurmin, the micronized curcumin platform in ImmuCurc, GeLiPthin-1 and Cortexa, shows 89 mg/mL water solubility against roughly 1–2 mg/mL for standard curcumin extract. COMPLIANCE NOTE: both are absorption measurements. Neither is evidence of a health outcome, and the study design must travel with any figure you quote.

Key takeaway for affiliates: Micro Matrix is the technology spine that connects all MN Nutra products. It's what makes MN Nutra a platform company, not just a supplement brand. When explaining to customers, focus on 'better absorption means your body can actually use what you're taking' — but never claim it cures or treats any disease.

Stage 1 — Raw Material Selection: Only GRAS (Generally Recognized As Safe) excipients accepted by major regulatory authorities worldwide. Each ingredient is sourced with certificates of analysis, identity testing, and heavy metal screening.

Stage 2 — Micronization: Active compounds are reduced to controlled particle sizes (target: ≥80% of particles ≤10 µm for beta-glucan; similar specifications for curcumin and CBD from hemp). This dramatically increases surface area for dissolution.

Stage 3 — Matrix Formation: Micronized actives are embedded within a proprietary solid matrix using specific surfactant-to-active ratios. This creates a stable micro-network that protects the active during storage and transit through the stomach.

Stage 4 — Amorphous Conversion: Where applicable, crystalline compounds are converted to amorphous form during matrix embedding. Amorphous forms dissolve faster than crystalline equivalents because they lack the energy barrier of crystal lattice disruption.

Stage 5 — Stability Optimisation: Each batch undergoes accelerated stability testing. The matrix must maintain particle size distribution, dissolution profile, and assay values through the product's shelf life (typically 24–36 months).

Stage 6 — Finished Dosage Form: The stabilised matrix is filled into capsules, compressed into tablets, or formulated as powder sachets depending on the product line. Each format is tested for dissolution, disintegration, and content uniformity.

Stage 7 — Quality Release: Final products are tested against specification for identity, assay, dissolution, microbiology, heavy metals, and stability. Only batches meeting all specifications are released for distribution.

Patent protection: MN Nutra's patent portfolio includes 65+ filings across PCT, US, European, and national jurisdictions (2019–2026). These cover the specific formulation compositions, not the general concept of micronization.

Key takeaway for affiliates: You don't need to explain all seven stages to customers. The simple message is: 'MN Nutra uses a patented manufacturing process that makes ingredients more absorbable, so your body gets more benefit from each dose.' Always reference that this is backed by a published human study.

Evidence hierarchy — what counts most: (1) Finished-product human studies in a healthy population, measuring an ordinary outcome. (2) Ingredient-level human studies, same conditions. (3) Preclinical and bioavailability characterisation. (4) Mechanistic data — explains why something should work.

LEVEL 1 — CBDNext Supra Capsule has a published finished-product human study (Journal of Cannabis Research, 2025): randomized three-way crossover, 9 healthy adults, single 40 mg dose, fed conditions. Two limits travel with it. It measured ABSORPTION, not a health outcome. And CBDNext is not one of the products you promote to consumers — none of the four supplements has a finished-product human study, so say that plainly if a customer asks.

LEVEL 2 — this is where the real substantiation sits, and it is where you should reach first. Saffron: a randomized placebo-controlled trial in healthy adults showing reduced snacking events over 8 weeks. Curcumin: improved working memory and attention in healthy older adults. PQQ: improved cognitive function scores in middle-aged and elderly subjects. Nicotinamide riboside: increased blood NAD+ levels in healthy subjects. Trans-resveratrol: increased cerebral blood flow in healthy adults. Green tea catechins and capsaicinoids: increased energy expenditure in healthy subjects. Every one of these was run in people who were not patients, and measured an ordinary outcome.

LEVEL 3 — NovoCurmin: 89 mg/mL water solubility and improved Cmax versus standard curcumin, from preclinical characterisation. This substantiates the delivery technology. It does not substantiate a health outcome.

LEVEL 4 — mechanism. Dectin-1 receptor recognition of micronized beta-glucan in gut-associated lymphoid tissue. Saccharomyces boulardii as a non-colonising probiotic yeast supporting gut flora balance. Curcumin and NF-kB signalling. Mechanism explains the formulation rationale; it is not evidence of an effect.

WHAT MAY NEVER BE CITED: any study conducted in a patient population, or measuring a disease outcome. The micronized beta-glucan dossier is the case to know — every endpoint in it is a disease outcome, so none of it may be used, in any framing, including as an ingredient study or as a link. The same applies to the GeLiPthin-1 animal study and to any berberine, NMN or resveratrol trial run in a clinical population.

Key takeaway for affiliates: be honest about the evidence level, and reach for the Level 2 studies. They are in healthy people, they measure ordinary outcomes, and they support exactly the claims you are allowed to make. If you feel you need a disease study to close a sale, you are about to make a claim you may not make. Never say 'clinically proven' for any product in the range.

The FTC Act requires that advertising claims be truthful, not misleading, and substantiated. As an MN Nutra affiliate, you are legally responsible for the claims you make about our products.

APPROVED language (structure/function claims): 'Helps support healthy immune function' · 'Designed to support cognitive performance' · 'Formulated to help maintain healthy weight management' · 'May help support joint comfort' · 'Contains ingredients that support cellular energy production'. Always pair with the FDA disclaimer.

PROHIBITED language (disease claims — NEVER use): 'Cures cancer' · 'Treats diabetes' · 'Prevents Alzheimer's' · 'Reduces tumour size' · 'Lowers blood pressure' · 'Heals inflammation' · 'Anti-viral' · 'Fights COVID'. Any claim that a supplement diagnoses, treats, cures, or prevents a disease is illegal under DSHEA.

Required FDA disclaimer (must appear with any structure/function claim): '*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.'

Testimonial rules: Never fabricate customer reviews or testimonials. If sharing your own experience, it must be truthful and include: 'Individual results may vary.' Never claim typical results unless supported by adequate substantiation.

Income claims: Never guarantee income from the affiliate program. If discussing earnings, you must disclose that results vary and include average earnings data if available. The FTC requires that income claims reflect typical results, not exceptional ones.

Social media requirements: All paid partnerships and affiliate relationships must be clearly disclosed using #ad, #sponsored, or 'Paid partnership with MN Nutra' — placed where viewers will see it before engaging with the content (not buried in hashtags).

Escalation protocol: If a customer asks whether a product can help with a specific medical condition, respond: 'I'm not qualified to give medical advice. Please consult your healthcare provider. I can share information about the ingredients and the published research if that's helpful.' Never diagnose or prescribe.

Key takeaway: When in doubt, ask yourself: 'Am I claiming this product treats or prevents a disease?' If yes, don't say it. Stick to structure/function language ('helps support'), always include the FDA disclaimer, and always disclose your affiliate relationship.